Sabatolimab (also referred to as MBG453) is a high-affinity, ligand-blocking, humanized anti-TIM-3 IgG4 (S228P) antibody currently in clinical evaluation for patients with myeloproliferative disorders, including AML and MDS. This evidence concerns the gene HAVCR2 and acute myeloid leukemia.